ABK Biomedical, Inc., a Halifax, Nova Scotia, Canada-based medical device company dedicated to the research, development and commercialization of innovative embolic therapies, raised $30m in Series B funding.
The round was co-led by F-Prime Capital and Varian Medical Systems.
The company will use the funds to support the research and development, manufacturing, and clinical development program designed for regulatory submission of both Eye90™ and Easi-Vue™.
Led by Mike Mangano, president and CEO, ABK Biomedical is organized to research, develop and commercialize breakthrough medical device therapies to improve treatment outcomes and the lives of patients with benign and malignant hypervascular tumors. Specifically, the company holds intellectual property in the focus area of inorganic polymer microspheres, targeted at the field of embolotherapy within the Interventional Radiology/Interventional Oncology medical disciplines. ABK Biomedical possesses advanced intellectual capital and its own R&D and manufacturing facilities for developing and commercializing embolotherapy products.
It is advancing
– Eye90™ microspheres, which are designed for transarterial radiation therapy for liver tumors, and
– Easi-Vue™ microspheres for bland embolic treatment of hypervascular tumors.